Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04160390 · ClinicalTrials.gov registry record
Blood Samples to Identify Biomarkers in Patients Treated With Cyclophosphamide After Donor Stem Cell Transplant
A clinical trial of Malignant Neoplasm and Allogeneic Hematopoietic Stem Cell Transplant Recipient, sponsored by City of Hope Medical Center.
- Active
- Registry status
- 72
- Enrollment target
- 1
- Study location
NCT04160390 is a study of Malignant Neoplasm and Allogeneic Hematopoietic Stem Cell Transplant Recipient that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 72 participants, below the 512-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04160390, a study of Malignant Neoplasm and Allogeneic Hematopoietic Stem Cell Transplant Recipient, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial uses blood samples to understand how patients' bodies process and respond to a drug called cyclophosphamide given after a donor stem cell transplant. Identifying biomarkers (molecules that can indicate normal or abnormal processes) may help researchers develop a blood test that can be used to predict how well patients will process and respond to cyclophosphamide.
Conditions Studied
Interventions
- OTHER Biospecimen Collection-Blood
- OTHER Biospecimen Collection-Stool
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2018-11-13 |
| Est. Completion | 2027-04-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04160390
The ClinicalTrials.gov registry entry for NCT04160390 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 512-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (86% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Malignant Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Biospecimen Collection-Blood is the first listed.
NCT04160390 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04160390 about?
NCT04160390 is a clinical study titled "Blood Samples to Identify Biomarkers in Patients Treated With Cyclophosphamide After Donor Stem Cell Transplant". This trial uses blood samples to understand how patients' bodies process and respond to a drug called cyclophosphamide given after a donor stem cell transplant. Identifying biomarkers (molecules that can indicate normal or abnormal processes) may help researchers develop a blood test that can be use...
What is the current status of trial NCT04160390?
This trial is currently active not recruiting. The enrollment target is 72 participants. The study started on 2018-11-13. Estimated completion is 2027-04-24.
What conditions does trial NCT04160390 study?
This clinical trial studies the following conditions: Malignant Neoplasm, Allogeneic Hematopoietic Stem Cell Transplant Recipient, Donor.
What interventions are being tested in trial NCT04160390?
The interventions under investigation include: Biospecimen Collection-Blood (OTHER), Biospecimen Collection-Stool (OTHER).
Who is sponsoring clinical trial NCT04160390?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04160390 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
RECRUITING · Phase 1
-
Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases
RECRUITING · Phase 3
-
Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer
RECRUITING
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing
RECRUITING · NA
-
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
RECRUITING · Phase 1
Explore more on PlainTrial
Malignant Neoplasm
All registered trials for this condition
Allogeneic Hematopoietic Stem Cell Transplant Recipient
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.